Podcast appearances and mentions of David W Parke

In this episode, David W. Parke II, MD, sits down with hosts, Jim Mazzo and John A. Hovanesian, MD, FACS, to discuss stepping down as the American Academy of Ophthalmology CEO, the highlights of what he accomplished during this time, and his thoughts on the future of ophthalmology. Welcome to the Eyeluminaries podcast :10 News and notes with John and Jim 1:30 Allergan's Vuity presbyopia-correcting drop gains FDA approval 1:36 Glaukos' two phase 2 clinical trials for dry eye disease and presbyopia 3:30 Acufocus' receives “approvable” letter on IC-8 IOL 5:42 Harrow Health acquires four ophthalmic drugs from Novartis 8:40 Welcome David Parke 10:54 What's it like having three generations of ophthalmologists in your family? 11:27 Why leave the AAO presidency now? What's the significance of 2022? 13:29 Tell us some of the highlights what are you most proud of during those past years 16:18 What are your thoughts on the consolidation from private equity? 19:55 As you look ahead to the future of ophthalmology, what worries you the most and what excites you the most, David? 25:17 What are your thoughts on the future of meetings? 31:23 Tell our listeners a little bit about what Verana Health does and what you'll be doing there 35:49 Thank you, David Parke! 40:26 Thanks for listening 41:00 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss Meditec and AMO. David W. Parke II, MD, is chairman of the board at Verana Health and former CEO of the American Academy of Ophthalmology. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field and specifically with Acufocus, Allergan, Glaukos and Novartis who were mentioned in this episode. Mazzo reports being an adviser for Anivive Lifesciences, Avellino, Bain Capital, CVC Capital, Zeiss Labs; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Centricity Vision, Crystilex, IanTech, Lensgen,  and Visus. Parke reports a financial interest in Verana Health.   

What role do professional organizations play in the COVID-19 crisis? NRR host John Kitchens, MD, invites AAO CEO David W. Parke II, MD, and AAO Immediate Past President George Williams, MD, to the program to discuss how the Academy is helping shepherd ophthalmologists through the current situation. Also joining Dr. Kitchens are Timothy G. Murray, MD, MBA, president of the ASRS, and J. Michael Jumper, MD, ASRS Chair of Education and the COVID-19 Task Force, who discuss how retina's largest organization is guiding its members to success.

What role do professional organizations play in the COVID-19 crisis? NRR host John Kitchens, MD, invites AAO CEO David W. Parke II, MD, and AAO Immediate Past President George Williams, MD, to the program to discuss how the Academy is helping shepherd ophthalmologists through the current situation. Also joining Dr. Kitchens are Timothy G. Murray, MD, MBA, president of the ASRS, and J. Michael Jumper, MD, ASRS Chair of Education and the COVID-19 Task Force, who discuss how retina's largest organization is guiding its members to success.

A conversation between the Academy's CEO/EVP David W. Parke II, MD, and ONE Network editor-in-chief Karl Golnik, MD. Dr. Parke discusses the new ethics code. The code is voluntary, and the Academy is among the first medical societies to adopt it. (May 2010)

A conversation between the Academy's CEO/EVP David W. Parke II, MD, and ONE Network editor-in-chief Karl Golnik, MD (October 2009)